Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Constellation Energy Corporation (CEG) Price & Performance

Amphastar Pharmaceuticals IncTrade
Constellation Energy CorporationTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Constellation Energy Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.44 (market cap $826.08M), while Constellation Energy Corporation trades at $255.67 (market cap $89.77B). The key difference: Constellation Energy Corporation is far larger — about 108.7× Amphastar Pharmaceuticals Inc's market cap, and Constellation Energy Corporation pays a 0.68% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMPHCEG
Market Cap
$826.08M$89.77B
Sector
HealthEnergy
52-Week High
$30.81$403.95
52-Week Low
$16.87$236.50
Enterprise Value
$1.22B$111.43B
Dividend Yield
0.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Constellation Energy Corporation

Constellation Energy (CEG) trades at $251.38, up 0.26% with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with 12.69% net margin and 16.33% ROE, supported by positive earnings beats in recent quarters. Analyst consensus remains strongly bullish with a $343.50 price target, representing 37% upside potential. Recent news highlights CEG's strategic positioning to benefit from AI-driven electricity demand and nuclear power resurgence.

CEG offers compelling growth exposure to clean energy transition with nuclear power advantages, though technical weakness and significant capital expenditures pose near-term challenges. The company's long-term power purchase agreements with major corporations provide revenue visibility, while valuation multiples remain reasonable relative to growth prospects. Execution on capital projects and regulatory developments represent key monitoring points for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Constellation Energy Corporation

Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.

Read more on CEG